Australian manufacturer thrives at intersection of technology and human wellbeing
From Manufacturers' Monthly:
Ringwood’s Trajan Scientific and Medical operates in two acknowledged areas of competitive advantage for Australia: advanced manufacturing and medical technology. Brent Balinski spoke to company CEO Stephen Tomisich about how it plans to change the world of healthcare.
Read the full article at Manufacturers' Monthly: Australian manufacturer thrives at intersection of technology and human wellbeing
Stephen Tomisich, Director and Chief Executive Officer, Trajan Scientific and Medical
Also in News
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
European patent for Trajan’s hemaPEN
US FDA listing of Trajan’s hemaPEN blood microsampling device
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.